ClinicalTrials.gg
CompletedNCT01443845Updated Apr 13, 2017Results posted

Roflumilast in Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Fixed Dose Combinations of Long-acting β2-agonist (LABA) and Inhaled Corticosteroid (ICS)

A Phase 4 interventional study of Roflumilast and Placebo in COPD, COPD Exacerbation and Lung Diseases, sponsored by AstraZeneca. Completed at 338 sites in 17 countries. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2017-04-13.

Sponsored by AstraZeneca · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
2,354
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 32 studies testing roflumilast in Pulmonary Disease, Chronic Obstructive — 1 open to participants now, 1 under way, none of them phase 3. Roflumilast · Pulmonary Disease, Chronic Obstructive.

Enrollment
Largest of 32
2,354 · median 154
Started
2011
with 4 others
Phase 4
8 of 32
1 open now
Registered
15th of 32
by date
Lead sponsor
18 of 32
AstraZeneca

Among the 32 studies testing roflumilast in Pulmonary Disease, Chronic Obstructive, this one has the largest enrollment, is one of 5 that started in 2011, is one of 8 in phase 4, and was the 15th registered.

Pulmonary Disease, Chronic Obstructive

5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 856 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

1 of the 32 studies testing roflumilast in Pulmonary Disease, Chronic Obstructive is open now. Recruiting first, the newest first:

About roflumilast

Roflumilast: first FDA approval 2011 (DALIRESP), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 558 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 88 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 32 studies testing roflumilast in Pulmonary Disease, Chronic Obstructive, or all of them as a file.
02

Study summary

To demonstrate the additional benefit of roflumilast when added on to fixed-dose combination (FDC) LABA/ICS in the reduction of exacerbations in subjects with severe to very severe COPD.

03

Conditions studied

  • COPD
  • COPD Exacerbation
  • Lung Diseases
  • Respiratory Disorders
  • Pulmonary Disease
  • Chronic Obstructive Lung Diseases
  • Chronic Obstructive Airway Disease

Keywords

  • COPD
  • Exacerbations
  • Roflumilast
  • Daliresp
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

    1. Male or female patients at least 40 years of age
    1. History of (according to Global Initiative for Chronic Obstructive Lung Disease [GOLD] 2010) for at least 12 months prior to Screening (Visit 1) associated with chronic productive cough for 3 months in each of 2 consecutive years (with other causes of productive cough excluded). Only patients with chronic bronchitis will be included (concomitant emphysema is permitted)
    1. Forced expiratory volume after 1 second ()/forced vital capacity (FVC) ratio (postbronchodilator) \< 70% at Screening (Visit 1)
    1. FEV1 (postbronchodilator) ≤ 50% of predicted at Screening (Visit 1)
    1. At least two documented moderate or severe COPD exacerbations within 12 months prior to Screening (Visit 1)
    1. Patients must be on FDC LABA/ICS treatment ≥ 3 months prior to Screening (Visit 1)
    1. Former smokers (defined as smoking cessation at least 1 year ago) or current smokers (including patients who ceased smoking within the past year) both with a smoking history of at least 20 pack-years

Exclusion criteria

Exclusion Criteria:

    1. Moderate or severe exacerbation and/or COPD exacerbations treated with antibiotics or systemic glucocorticosteroids within 4 weeks of Screening (Visit 1) (ie, patients must be clinically stable)
    1. Known alpha-1-antitrypsin deficiency
    1. Current diagnosis of asthma (either controlled or uncontrolled) (Note: History of childhood asthma is not exclusionary.)
    1. (BMI) ≥ 45 kg/m2
    1. Patients with a history (within 5 years) or current diagnosis of cancer other than basal or squamous cell skin cancer
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
2,354 participants (actual)

Study arms

  • Experimental
    1

    Roflumilast

    Drug: Roflumilast

  • Placebo comparator
    2

    Placebo

    Drug: Placebo

Interventions

  • Roflumilast 500 µg, oral administration, once per day

    Also known as: Daliresp

  • DrugPlacebo

    Dose-matched placebo, oral administration, once per day.

06

What researchers measure

Primary outcomes

  1. Rate of Moderate or Severe COPD Exacerbations Per Patient Per Year.

    Rate of moderate or severe COPD exacerbations, defined as requiring oral or parenteral glucocorticosteroids (moderate) or requiring hospitalization and/or leading to death (severe), during the double-blind treatment period.

    Time frame: Baseline to Week 52

Secondary outcomes

  1. Rate of COPD Exacerbations That Led to Hospitalization or Death (ie, Severe COPD Exacerbations)

    Rate of moderate or severe COPD exacerbations, defined as requiring hospitalization and/or leading to death (severe), during the double-blind treatment period.

    Time frame: Week 0 (Visit 2) to Week 52

  2. Rate of Moderate or Severe COPD Exacerbations or COPD Exacerbations Treated With Antibiotics

    Rate of moderate or severe COPD exacerbations treated with antibiotics during the double-blind treatment period.

    Time frame: Week 0 (Visit 2) to Week 52

  3. Mean Change in Predose Forced Expiratory Volume in 1 Second (FEV1)

    Mean change from randomization (Visit 2) over 52 weeks of treatment in predose forced expiratory volume in 1 second (FEV1)

    Time frame: Week 0 (Visit 2) to Week 52

07

Results

Posted Jan 25, 2017

Participant flow

Recruitment occurred from September 2011 to October 2014 for a total of 380 study centers screened patients for the study: Italy, Spain, United States, Ukraine, Argentina, Russia, Philippines, Romania, Serbia, Canada, Malaysia, Thailand, Mexico, Peru and Taiwan.

Participant flow — Overall Study
MilestonePlaceboRoflumilast
Started11761178
Completed922841
Not completed254337
Withdrew: Protocol violation4345
Withdrew: Other reasons, such as copd exacerbation4444
Withdrew: Deterioration in pulmonary function14
Withdrew: Lack of efficacy105
Withdrew: Adverse event64138
Withdrew: Withdrawal by subject6367
Withdrew: Military conflict - site terminated2021
Withdrew: Lost to follow-up913

Outcome measures

PrimaryRate of Moderate or Severe COPD Exacerbations Per Patient Per Year.

Rate of moderate or severe COPD exacerbations, defined as requiring oral or parenteral glucocorticosteroids (moderate) or requiring hospitalization and/or leading to death (severe), during the double-blind treatment period.

Time frame:
Baseline to Week 52
Reported as:
Number · COPD exacerbations per patient per year
Rate of Moderate or Severe COPD Exacerbations Per Patient Per Year.
COPD exacerbations per patient per yearPlaceboRoflumilast
Rate of Moderate or Severe COPD Exacerbations Per Patient Per Year.1.27 (1.17 to 1.39)1.17 (1.06 to 1.28)
Statistical analysis
  • Placebo vs Roflumilast · negative binomial regression · p = 0.1634 · Rate ratio: 0.92 · 95% CI 0.81 to 1.04p-values are based on a negative binomial regression with factors Treatment and LAMA use.
  • Placebo vs Roflumilast · negative binomial regression · p = 0.0195 · Rate ratio: 0.83 · 95% CI 0.71 to 0.97
  • Placebo vs Roflumilast · negative binomial regression · p = 0.3164 · Rate ratio: 1.11 · 95% CI 0.91 to 1.35
  • Placebo vs Roflumilast · negative binomial regression · p = 0.0385 · Rate ratio: 0.85 · 95% CI 0.74 to 0.99
  • Placebo vs Roflumilast · negative binomial regression · p = 0.6475 · Rate ratio: 1.05 · 95% CI 0.84 to 1.32
SecondaryRate of COPD Exacerbations That Led to Hospitalization or Death (ie, Severe COPD Exacerbations)

Rate of moderate or severe COPD exacerbations, defined as requiring hospitalization and/or leading to death (severe), during the double-blind treatment period.

Time frame:
Week 0 (Visit 2) to Week 52
Reported as:
Number · COPD exacerbations per patient per year
Rate of COPD Exacerbations That Led to Hospitalization or Death (ie, Severe COPD Exacerbations)
COPD exacerbations per patient per yearPlaceboRoflumilast
Rate of COPD Exacerbations That Led to Hospitalization or Death (ie, Severe COPD Exacerbations)0.29 (0.25 to 0.34)0.28 (0.23 to 0.33)
Statistical analysis
  • Placebo vs Roflumilast · negative binomial regression · p = 0.6354 · Rate ratio: 0.95 · 95% CI 0.75 to 1.19
SecondaryRate of Moderate or Severe COPD Exacerbations or COPD Exacerbations Treated With Antibiotics

Rate of moderate or severe COPD exacerbations treated with antibiotics during the double-blind treatment period.

Time frame:
Week 0 (Visit 2) to Week 52
Reported as:
Number · COPD Exacerbations per Patient per Year
Rate of Moderate or Severe COPD Exacerbations or COPD Exacerbations Treated With Antibiotics
COPD Exacerbations per Patient per YearPlaceboRoflumilast
Rate of Moderate or Severe COPD Exacerbations or COPD Exacerbations Treated With Antibiotics1.45 (1.34 to 1.57)1.31 (1.20 to 1.43)
Statistical analysis
  • Placebo vs Roflumilast · negative binomial regression · p = 0.0884 · Rate ratio: 0.9 · 95% CI 0.8 to 1.02
SecondaryMean Change in Predose Forced Expiratory Volume in 1 Second (FEV1)

Mean change from randomization (Visit 2) over 52 weeks of treatment in predose forced expiratory volume in 1 second (FEV1)

Time frame:
Week 0 (Visit 2) to Week 52
Reported as:
Least squares mean · Liters
Mean Change in Predose Forced Expiratory Volume in 1 Second (FEV1)
LitersPlaceboRoflumilast
Mean Change in Predose Forced Expiratory Volume in 1 Second (FEV1)-0.0091 ± 0.00470.0441 ± 0.0048
Statistical analysis
  • Placebo vs Roflumilast · Mixed Model for Repeated Measures (MMRM) · p = < 0.0001 (The MMRM analysis is based on all postbaseline observed data using a mixed model with terms for treatment, baseline, visit, LAMA use, treatment-by-visit and baseline-by-visit interactions.) · Mean difference (final values): 0.0532 · 95% CI 0.04 to 0.0664

Adverse events

Collected over Adverse event data was collected from the start of the 52-week double-blind treatment period, to 30 days after the end of treatment.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—162/1,174 (13.8%)188/1,174 (16%)
Roflumilast—180/1,178 (15.3%)317/1,178 (26.9%)
Most frequent serious events
Showing 10 of 338
Most frequent serious events
EventPlaceboRoflumilast
PneumoniaInfections and infestations45/117447/1178
Lobar pneumoniaInfections and infestations7/11741/1178
Acute myocardial infarctionCardiac disorders1/11747/1178
Acute respiratory failureRespiratory, thoracic and mediastinal disorders6/11747/1178
Respiratory failureRespiratory, thoracic and mediastinal disorders5/11747/1178
Non-cardiac chest painGeneral disorders3/11746/1178
Atrial fibrillationCardiac disorders5/11744/1178
Cardiac arrestCardiac disorders0/11745/1178
Gastrointestinal haemorrhageGastrointestinal disorders1/11745/1178
FallInjury, poisoning and procedural complications4/11743/1178
Most frequent other events
Most frequent other events
EventPlaceboRoflumilast
DiarrhoeaGastrointestinal disorders36/1174119/1178
Weight decreasedInvestigations27/117491/1178
HeadacheNervous system disorders48/117480/1178
Upper respiratory tract infectionInfections and infestations66/117460/1178
NauseaGastrointestinal disorders30/117462/1178

Baseline characteristics

The demographic information provided here is for the safety population. The safety population (numbering 2352 patients) of the trial does not include 2 patients from the enrolled population (numbering 2354 patients), due to a protocol deviation for one patient and an adverse event for a second patient, both in the placebo arm

Age, Continuous
Age, Continuous(years)PlaceboRoflumilastTotal
Mean64.5 ± 8.464.4 ± 8.864.5 ± 8.6
Age, Customized
Age, Customized(Participants)PlaceboRoflumilastTotal
Adults 40-65 years6346401274
Adults over 65 years5405381078
Sex/Gender, Customized
Sex/Gender, Customized(Participants)PlaceboRoflumilastTotal
Male7948211615
Female380357737
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)PlaceboRoflumilastTotal
White9449351879
Black or African American273562
Asian170167337
American Indian or Alaska Native61622
Native Hawaiian or Other Pacific Islander022
Other272350
Region of Enrollment
Region of Enrollment(participants)PlaceboRoflumilastTotal
Colombia71017
Argentina197198395
Russian Federation7777154
Romania5554109
United States458457915
Philippines130131261
Ukraine9595190
Malaysia6713
Thailand181634
Spain6612
Canada141529
Taiwan7613
Italy011
Mexico222244
Serbia474794
Peru353671
Ethnicity
Ethnicity(Participants)PlaceboRoflumilastTotal
Hispanic or Latino272268540
Not Hispanic or Latino9029101812
ICS/LABA Therapy
ICS/LABA Therapy(Participants)PlaceboRoflumilastTotal
Advair7667681534
Symbicort408410818
Long-acting muscarinic antagonist(s) (LAMA) use
Long-acting muscarinic antagonist(s) (LAMA) use(Participants)PlaceboRoflumilastTotal
LAMA5465481094
No-LAMA6286301258

4 further baseline measures are reported on the registry.

08

Study locations

338 sites
  • Forest Investigative Site 081
    Anniston, Alabama 36207, United States
  • Forest Investigative Site 065
    Athens, Alabama 35611, United States
  • Forest Investigative Site 131
    Florence, Alabama 35630, United States
  • Forest Investigative Site 073
    Mobile, Alabama 36608, United States
  • Forest Investigative Site 272
    Mesa, Arizona 85206, United States
  • Forest Investigative Site 091
    Peoria, Arizona 85381, United States
  • Forest Investigative Site 034
    Phoenix, Arizona 85018, United States
  • Forest Investigative Site 188
    Phoenix, Arizona 85020, United States
  • Forest Investigative Site 211
    Phoenix, Arizona 85028, United States
  • Forest Investigative Site 247
    Phoenix, Arizona 85050, United States
  • Forest Investigative Site 208
    Fort Smith, Arkansas 72901, United States
  • Forest Investigative Site 101
    Little Rock, Arkansas 72205, United States
  • Forest Investigative Site 074
    Bellflower, California 90706, United States
  • Forest Investigative Site 060
    Fresno, California 93721, United States
  • Forest Investigative Site 329
    Fresno, California 93726, United States
  • Forest Investigative Site 245
    Fullerton, California 92835, United States
  • Forest Investigative Site 310
    Garden Grove, California 92844, United States
  • Forest Investigative Site 297
    Lakewood, California 90712, United States
  • Forest Investigative Site 116
    Long Beach, California 90822, United States
  • Forest Investigative Site 085
    Los Angeles, California 90048, United States
  • Forest Investigative Site 241
    Los Angeles, California 90073, United States
  • Forest Investigative Site 299
    Northridge, California 91325, United States
  • Forest Investigative Site 213
    Palo Alto, California 94555, United States
  • Forest Investigative Site 268
    Pismo Beach, California 93449, United States
  • Forest Investigative Site 025
    Riverside, California 92506, United States
  • Forest Investigative Site 143
    Roseville, California 95661, United States
  • Forest Investigative Site 104
    Sacramento, California 95817, United States
  • Forest Investigative Site 352
    San Diego, California 92117, United States
  • Forest Investigative Site 038
    San Diego, California 92120, United States
  • Forest Investigative Site 326
    San Jose, California 95124, United States
  • Forest Investigative Site 209
    Torrance, California 90502, United States
  • Forest Investigative Site 331
    Stamford, Connecticut 06902, United States
  • Forest Investigative Site 017
    Waterbury, Connecticut 06708, United States
  • Forest Investigative Site 124
    Newark, Delaware 19713, United States
  • Forest Investigative Site 196
    Brandon, Florida 33511, United States
  • Forest Investigative Site 224
    Brandon, Florida 33511, United States
  • Forest Investigative Site 358
    Brandon, Florida 33511, United States
  • Forest Investigative Site 166
    Chiefland, Florida 32626, United States
  • Forest Investigative Site 111
    Clearwater, Florida 33756, United States
  • Forest Investigative Site 123
    Clearwater, Florida 33765, United States
  • Forest Investigative Site 291
    Coral Gables, Florida 33134, United States
  • Forest Investigative Site 239
    DeFuniak Springs, Florida 32435, United States
  • Forest Investigative Site 001
    Fort Lauderdale, Florida 33316, United States
  • Forest Investigative Site 165
    Fort Walton Beach, Florida 32547, United States
  • Forest Investigative Site 102
    Gainesville, Florida 32608, United States
  • Forest Investigative Site 003
    Hollywood, Florida 33024, United States
  • Forest Investigative Site 023
    Jacksonville, Florida 32216, United States
  • Forest Investigative Site 077
    Kissimmee, Florida 34741, United States
  • Forest Investigative Site 330
    Kissimmee, Florida 34741, United States
  • Forest Investigative Site 027
    Miami, Florida 33015, United States
  • Forest Investigative Site 229
    Miami, Florida 33136, United States
  • Forest Investigative Site 115
    Miami, Florida 33175, United States
  • Forest Investigative Site 339
    Miami, Florida 33186, United States
  • Forest Investigative Site 092
    Naples, Florida 34119, United States
  • Forest Investigative Site 004
    Orlando, Florida 32822, United States
  • Forest Investigative Site 187
    Ormond Beach, Florida 32174, United States
  • Forest Investigative Site 069
    Pensacola, Florida 32504, United States
  • Forest Investigative Site 161
    Ponte Vedra, Florida 32081, United States
  • Forest Investigative Site 087
    Port Orange, Florida 32127, United States
  • Forest Investigative Site 357
    Saint Petersburg, Florida 33744, United States
  • Forest Investigative Site 109
    St. Cloud, Florida 34769, United States
  • Forest Investigative Site 121
    St. Petersburg, Florida 33704, United States
  • Forest Investigative Site 002
    Tamarac, Florida 33312, United States
  • Forest Investigative Site 287
    Tampa, Florida 33607, United States
  • Forest Investigative Site 052
    Tampa, Florida 33613, United States
  • Forest Investigative Site 011
    Winter Park, Florida 32789, United States
  • Forest Investigative Site 348
    Winter Park, Florida 32792, United States
  • Forest Investigative Site 103
    Canton, Georgia 30114, United States
  • Forest Investigative Site 292
    Dawsonville, Georgia 30534, United States
  • Forest Investigative Site 042
    Duluth, Georgia 30096, United States
  • Forest Investigative Site 140
    Gainesville, Georgia 30501, United States
  • Forest Investigative Site 030
    Lawrenceville, Georgia 30046, United States
  • Forest Investigative Site 321
    Woodstock, Georgia 30189, United States
  • Forest Investigative Site 008
    Coeur d' Alene, Idaho 83814, United States
  • Forest Investigative Site 119
    Eagle, Idaho 83616, United States
  • Forest Investigative Site 201
    Bolingbrook, Illinois 60490, United States
  • Forest Investigative Site 206
    Downers Grove, Illinois 60515, United States
  • Forest Investigative Site 136
    Elk Grove Village, Illinois 60007, United States
  • Forest Investigative Site 139
    Oak Lawn, Illinois 60453, United States
  • Forest Investigative Site 227
    Peoria, Illinois 61637, United States
  • Forest Investigative Site 334
    Springfield, Illinois 62703, United States
  • Forest Investigative Site 263
    Elwood, Indiana 46036, United States
  • Forest Investigative Site 342
    Lafayette, Indiana 47904, United States
  • Forest Investigative Site 293
    Michigan City, Indiana 46360, United States
  • Forest Investigative Site 264
    Muncie, Indiana 47303, United States
  • Forest Investigative Site 135
    Council Bluffs, Iowa 51503, United States
  • Forest Investigative Site 256
    Iowa City, Iowa 52242, United States
  • Forest Investigative Site 214
    Olathe, Kansas 66061, United States
  • Forest Investigative Site 316
    Topeka, Kansas 66606, United States
  • Forest Investigative Site 301
    Wichita, Kansas 67205, United States
  • Forest Investigative Site 051
    Bowling Green, Kentucky 42101, United States
  • Forest Investigative Site 075
    Crescent Springs, Kentucky 41017, United States
  • Forest Investigative Site 351
    Hazard, Kentucky 41701, United States
  • Forest Investigative Site 068
    Lexington, Kentucky 40504, United States
  • Forest Investigative Site 088
    Louisville, Kentucky 40215, United States
  • Forest Investigative Site 053
    Owensboro, Kentucky 42303, United States
  • Forest Investigative Site 273
    Lafayette, Louisiana 70503, United States
  • Forest Investigative Site 070
    Opelousas, Louisiana 70570, United States
  • Forest Investigative Site 097
    Sunset, Louisiana 70584, United States
  • Forest Investigative Site 128
    Lewiston, Maine 04240, United States

Showing the first 100 of 338 sites across 17 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Martinez FJ, Rabe KF, Calverley PMA, Fabbri LM, Sethi S, Pizzichini E, McIvor A, Anzueto A, Alagappan VKT, Siddiqui S, Reisner C, Zetterstrand S, Roman J, Purkayastha D, Bagul N, Rennard SI. Determinants of Response to Roflumilast in Severe Chronic Obstructive Pulmonary Disease. Pooled Analysis of Two Randomized Trials. Am J Respir Crit Care Med. 2018 Nov 15;198(10):1268-1278. doi: 10.1164/rccm.201712-2493OC. PubMed 29763572 ↗
  • Karpefors M, Weatherall J. The Tendril Plot-a novel visual summary of the incidence, significance and temporal aspects of adverse events in clinical trials. J Am Med Inform Assoc. 2018 Aug 1;25(8):1069-1073. doi: 10.1093/jamia/ocy016. PubMed 29579254 ↗
  • Martinez FJ, Rabe KF, Sethi S, Pizzichini E, McIvor A, Anzueto A, Alagappan VK, Siddiqui S, Rekeda L, Miller CJ, Zetterstrand S, Reisner C, Rennard SI. Effect of Roflumilast and Inhaled Corticosteroid/Long-Acting beta2-Agonist on Chronic Obstructive Pulmonary Disease Exacerbations (RE(2)SPOND). A Randomized Clinical Trial. Am J Respir Crit Care Med. 2016 Sep 1;194(5):559-67. doi: 10.1164/rccm.201607-1349OC. PubMed 27585384 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2011 to primary completion in Nov 2015, 50 months.

Results were first posted in Jan 2017, 1 year 1 month after primary completion.

Of 71 industry-sponsored phase 4 interventional studies under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 22. This study's 50 months is above that.

Counting every sponsor, half of 157 studies reached it within 19 months; a quarter within 12 and three quarters within 40.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 28, 2011
First posted
Sep 30, 2011
StartActual
Sep 30, 2011
Primary completionActual
Nov 30, 2015
CompletionActual
Jan 31, 2016
Results first posted
Jan 25, 2017
Last update
Apr 13, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 13, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01443845
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Sep 30, 2011
Start date
Sep 30, 2011
Primary completion
Nov 30, 2015
Completion
Jan 31, 2016
Results posted
Jan 25, 2017
Last update
Apr 13, 2017

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Roflumilast

Start the discussion